Viridian Therapeutics has spent years moving its thyroid eye disease (TED) hopeful, veligrotug, through clinical trials a | Viridian aims to challenge Amgen in a blockbuster market, and it's now tapped Chinese CDMO giant WuXi Biologics in a manufacturing pact.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Viridian Therapeutics has scored an FDA
WuXi Biologics has secured a five-year contract with Viridian Therapeutics to manufacture and supply commercial batches of its…
The FDA, through a new approval, gave Viridian's drug a label that some on Wall Street believe makes it well-positioned to…
FDA approves Viridian Therapeutics' Lumvoa for thyroid eye disease. Immediate commercial launch scheduled with full patient…
Outlook Therapeutics has notched a win in its uphill battle to commercialize an ophthalmic version of Roche’s Avastin…
As Amgen prepares to defend Tavneos’ market approval in the U.S., the company has received a bad omen overseas, with regulators…
